The global canine flu therapeutics market is set for steady growth, with its valuation projected to rise from USD2.04 billion in 2023 to USD3.06 billion by 2033. This reflects a compound annual growth rate (CAGR) of 4.1% over the forecast period. The increasing awareness of pet healthcare, along with the rising incidence of canine influenza, is driving the demand for effective treatment options.
Canine influenza, caused by the H3N8 and H3N2 strains of the virus, is a contagious respiratory disease that affects dogs worldwide. As pet adoption increases, so does the emphasis on pet health and wellness, leading to higher demand for canine flu therapeutics. Pet owners are becoming more proactive in seeking preventive measures and timely treatment, especially as outbreaks of canine influenza become more common in animal shelters, boarding facilities, and dog parks.
Veterinary pharmaceutical companies are focusing on the development of advanced therapeutics to treat and prevent the spread of canine influenza. Vaccines, antiviral medications, and supportive treatments are being introduced to ensure effective management of the disease. Government initiatives and increased funding for veterinary healthcare are also playing a role in fostering market growth.
Get the Comprehensive Full Report Now – https://www.futuremarketinsights.com/reports/canine-flu-therapeutics-market
Key Takeaways
- The global canine flu therapeutics market is projected to grow at a CAGR of 4.1%, reaching a market value of $3.06 billion by 2033.
- The market is driven by rising pet adoption, increased pet healthcare awareness, and a growing focus on veterinary preventive care.
- Canine influenza is caused by two main virus strains: H3N8 and H3N2, with both requiring targeted therapeutics for effective treatment.
- Growing investments in veterinary healthcare, along with the development of vaccines and antiviral drugs, are supporting market expansion.
As pet healthcare continues to gain prominence, the demand for canine flu therapeutics is expected to grow steadily. The focus on preventing outbreaks in high-risk areas such as shelters and boarding facilities, coupled with advancements in veterinary medicine, is set to provide lucrative growth opportunities for industry players.
Market Drivers
- Increasing Incidence of Canine Flu: The rising prevalence of canine influenza is driving demand for effective therapeutics, as more dogs are susceptible to infection through direct contact or respiratory discharges from infected animals.
- Pet Humanization Trend: As pet owners increasingly treat their pets as family members, there is a growing willingness to invest in their health and well-being, driving the demand for canine flu treatments.
- Government Support and Research Initiatives: Increased government support for veterinary health and ongoing research into canine influenza treatments are fostering market growth.
- Innovation in Therapeutics: The development of new treatment options, including vaccines and antiviral drugs, is enhancing the effectiveness of canine flu therapeutics.
Regional Insights
- North America: Expected to dominate the market with a share of approximately 37.6% in 2022, driven by high awareness and adoption rates of canine flu treatments.
- Europe: Anticipated to hold around 25.3% of the market share, supported by strong veterinary healthcare systems and increasing pet ownership.
Competitive Analysis
Market Players to Fuel Further Growth in the Canine Flu Therapeutics Market
The market is highly competitive due to the presence of several participants. The key players are adopting several growth strategies, and finding means to upgrade the vaccines that can cure influenza in animals faster and more cost-effectively.
Recent Developments
- In August 2021, Merck Animal Health announced a new name for its cattle vaccine portfolio, one of the industry’s prominent and most comprehensive vaccine portfolios. The goal of the new naming and packaging is to make it easier for customers to recognize the company’s vaccines and to identify specific formulations.
- In November 2020, Merck announced it had received a conditional license from the USDA to market Canine Influenza Vaccine H3N2- just one week after Zoetis received the same USDA nod for its vaccine. Both new vaccines require two doses, administered a few weeks apart.
- In October 2018, the European Clinical Office was approved to utilize serological hemagglutination hindrance (HI) for flu testing.
- Boehringer Ingelheim International GmbH has decided to expand veterinary vaccine capacity for rising transboundary diseases in France.
Key Players
- Interver Inc
- Merck Animal Health
- al Health
- GlaxoSmithKline Plc.
- Novartis AG
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- Sanofi
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
Key Segments Covered
By Drug Class:
- Antibiotics
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Antiviral Drugs
By Distribution Channel:
- Veterinary Clinics
- Veterinary Pharmacies
- Online Pharmacies
Key Regions Covered:
- North America
- United States
- Canada
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Europe
- Germany
- United Kingdom
- France
- Spain
- Russia
- Rest of Europe
- Japan
- Asia Pacific Excluding Japan
- China
- India
- Malaysia
- Singapore
- Australia
- Rest of Asia Pacific Excluding Japan (APEJ)
- The Middle East and Africa
- GCC Countries
- Israel
- South Africa
- Middle East and Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
